Nanobiotix (NASDAQ:NBTX) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $33.53 and traded as high as $34.77. Nanobiotix shares last traded at $34.53, with a volume of 130,038 shares traded.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Guggenheim initiated coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.67.

Nanobiotix Price Performance

The stock has a fifty day simple moving average of $33.01 and a two-hundred day simple moving average of $33.60.

Nanobiotix Company Profile

Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.

Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors.